Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Fulcrum Therapeutics Inc

Company price
3.685 USD -0.03 ( 0.67%)
Last update at 2026-11-20T21:00:00Z
VOLUME
1893640
Market Cap
288.40M

Momentum Score

…

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.68
Low
3.73
High
52 Week Price Range
2.83
Low
15.74
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies to modulate gene expression in genetically defined diseases, with a lead program targeting facioscapulohumeral muscular dystrophy (FSHD) and additional pipeline candidates. Long-term growth may be driven by positive clinical and regulatory milestones, pipeline expansion or partnerships, and the commercial potential of disease-modifying treatments in rare neuromuscular disorders.
Principal risks include binary clinical trial and regulatory outcomes, dependence on a small number of programs with ongoing financing needs, and limited commercial track record.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.71
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-56.10M
Debt / Equity
0.02
ROE
-32.38%
Net Debt
-191.09M
ROCE
-21.20%
Diluted EPS TTM
-1.21

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -74.88M -9.72M -97.33M -109.87M -80.85M
Net income -74.88M -9.72M -97.33M -105.62M -78.33M
Selling general administrative 28.67M 34.97M 39.15M 41.69M 30.52M
Selling and marketing expenses - 1.48M 2.52M - -
Gross profit -1.39M 16.61M -69.00M 6.34M 19.16M
Reconciled depreciation 1.39M 1.59M 2.25M 2.41M 2.52M
Ebit -74.88M -19.83M -97.33M -112.56M -83.57M
Ebitda -73.49M -18.24M -95.16M -111.71M -81.05M
Depreciation and amortization 1.39M 1.59M 2.17M 0.85M 2.52M
Operating income -84.77M -21.90M -110.66M -112.56M -81.05M
Other operating expenses 84.77M 101.90M 113.47M 118.48M 100.22M
Interest expense - - - 2.69M 2.72M
Non recurring - - - 0.43M -
Income tax expense - - 2.00M -4.25M -2.52M
Total revenue 0.00M 80.00M 2.81M 6.34M 19.16M
Total operating expenses 83.38M 38.51M 41.67M 118.48M 100.22M
Cost of revenue 1.39M 63.39M 71.80M - -
Total other income expense net 9.89M 12.17M 13.33M 2.69M 0.21M
Net income from continuing ops -74.88M -9.72M -98.71M -109.87M -80.85M
Net income applicable to common shares - - - -109.87M -80.85M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 366.28M 260.72M 257.69M 226.69M 235.00M
Other current assets 5.17M 5.56M 3.73M 4.37M 4.20M
Total liab 17.28M 17.68M 22.50M 27.74M 23.46M
Total stockholder equity 349.00M 243.03M 235.19M 198.94M 211.54M
Deferred long term liab - - - 4.62M -
Other current liab 9.05M 7.69M 8.73M 9.55M 0.07M
Common stock 0.07M 0.05M 0.06M 0.05M 0.04M
Capital stock 0.07M 0.05M 0.06M 0.05M 0.04M
Retained earnings -594.28M -519.40M -509.67M -412.34M -302.47M
Other liab - - - 0.20M 4.26M
Other assets - - - 3.20M 1.63M
Cash 197.53M 58.21M 25.56M 35.10M 35.41M
Total current liabilities 13.05M 11.04M 13.68M 16.73M 19.20M
Current deferred revenue - - - 0.93M 4.71M
Net debt -191.09M -49.58M -14.74M -21.68M -35.41M
Short term debt 2.40M 2.19M 2.19M 2.60M 9.63M
Short long term debt total 6.44M 8.63M 10.82M 13.42M 0.47M
Other stockholder equity 943.04M 762.25M 744.94M 612.02M 514.36M
Property plant equipment - - - 6.91M 7.37M
Total current assets 357.48M 249.92M 242.20M 207.52M 226.00M
Net tangible assets - - - 198.94M 211.54M
Short term investments 154.77M 182.81M 210.66M 167.82M 182.75M
Net receivables 1.07M 3.34M 2.25M 1.08M 4.11M
Inventory - - - -0.85M -0.47M
Accounts payable 1.59M 1.16M 2.76M 3.64M 4.79M
Accumulated other comprehensive income 0.17M 0.13M -0.14M -0.80M -0.40M
Common stock total equity - - - 0.05M 0.04M
Retained earnings total equity - - - -412.34M -302.47M
Non currrent assets other 1.74M 1.21M 2.01M 3.20M 1.63M
Non current assets total 8.80M 10.79M 15.49M 19.17M 9.00M
Capital lease obligations 6.44M 8.63M 10.82M 13.42M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 31.03M 32.23M -91.41M 14.38M -127.96M
Change to liabilities - - - -4.40M -10.25M
Total cashflows from investing activities 30.72M 32.23M -36.69M 12.41M -129.67M
Net borrowings - - - -0.05M -0.02M
Total cash from financing activities 168.67M 2.75M 118.12M 84.32M 186.51M
Change to operating activities - - - -1.55M 1.41M
Net income -74.88M -9.72M -97.33M -109.87M -80.85M
Change in cash 139.32M 32.76M -9.54M -0.31M -21.64M
Begin period cash flow 59.41M 26.66M 36.19M 36.50M 58.14M
End period cash flow 198.73M 59.41M 26.66M 36.19M 36.50M
Total cash from operating activities -60.06M -2.22M -90.97M -97.05M -78.48M
Issuance of capital stock 164.50M 0.00M 117.30M 80.80M 182.86M
Depreciation 1.39M 1.59M 2.17M 2.41M 2.52M
Change to inventory - - - - 1.25M
Change to account receivables 2.10M -1.56M -0.31M 2.50M -0.50M
Sale purchase of stock - - - 3.52M 3.67M
Other cashflows from financing activities - 2.75M 0.78M 3.52M 3.67M
Change to netincome - - - 13.35M 11.07M
Capital expenditures 0.31M 0.28M 0.51M 1.96M 1.71M
Change receivables - - - 3.41M -1.11M
Cash flows other operating - - - -2.10M -0.54M
Cash and cash equivalents changes - - - -0.31M -21.64M
Change in working capital 3.91M -4.25M -4.61M -3.09M -11.89M
Stock based compensation 12.47M 14.55M 14.80M 13.35M 11.07M
Other non cash items -2.95M -4.39M -5.99M 0.15M 0.67M
Free cash flow -60.38M -2.50M -91.47M -99.01M -80.19M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FULC
Fulcrum Therapeutics Inc
-0.03
0.67%
3.69 - - 2.66 0.93 117.40 -3.09
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

26 Landsdowne Street, Cambridge, MA, United States, 02139

617 651 8851

9

Name Title Year Born
Mr. Bryan E. Stuart Pres, CEO & Director 1976
Dr. Judith A. Dunn Ph.D. Interim Chief Medical Officer 1962
Dr. Bradley E. Bernstein M.D., Ph.D. Founder NA
Dr. Michael R. Green Founder NA
Dr. Rudolf Jaenisch M.D., Ph.D. Founder NA
Prof. Jeannie T. Lee M.D., Ph.D. Founder NA
Dr. Danny Reinberg Founder NA
Ms. Esther P. Rajavelu CFO & Treasurer 1979
Mr. Mel Hayes Chief Operating Officer 1970
Mr. Gregory Tourangeau Controller & Principal Accounting Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…